Anti-EGFR monoclonal antibody KSB 107
Alternative Names: Chimeric human:sheep monoclonal antibody KSB 107; KSB 102; KSB 107; Monoclonal antibody KSB 107; Project KSB 102Latest Information Update: 28 Jul 2004
At a glance
- Originator Xenova Group
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Jul 2004 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
- 25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group
- 22 May 2001 Preclinical development for Solid tumours in United Kingdom (Unknown route)